Pricing Log in Create free account
Saturday 7 November 2026 Export ICCC’s income statement to Excel — free account

ImmuCell Corporation

ICCC Healthcare Biotechnology

ImmuCell Corporation’s revenue for fiscal 2025 (year ended December 2025) was $27.6 million, up 4.34% from fiscal 2024.

Revenue
+11.5%
EPS
+233.3%
Free cash flow
+54.9%
Total debt
−15.3%

Quarter to June 2026, against a year earlier

9.90 0.05 −0.50%
Market cap
$90.4M
P/E
117×
Fwd P/E
−779×
Dividend yield
—
F-score
7/9
Altman Z
2.80
Beneish M
−3.10
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.16
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy 2 — — — — — 1 — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 37.45%

Capital & Financial Ratios $m

Size
Market Cap 90.37
Revenue ttm 30.68
Net income ttm 0.79
Free cash flow ttm 4.23
Net debt Q (0.56)
Valuation
P/E 117.02 (above 35: high)
Forward P/E (779.00) (negative: loss-making)
Price / sales 2.93
Forward P/S Powerpack
Price / FCF 21.21
Price / book 2.86
Financial health
Current ratio Q 4.75 (at or above 1.5: strong)
Debt / equity Q 0.26 (at or below 0.5: strong)
Interest coverage Q 0.00
Growth
Revenue growth Q +11.50% (above 0%: growing)
Operating income growth Q +239.69% (above 0%: growing)
EPS, this year —
EPS, next year A —
Revenue, next year A +25.15% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.9×, against a ten-year median of 2.9×; over the ten years it ranged from 1.5× in 2016 to 5.6× in 2021.
P/E against its own 10 years 71.30%
10-year low 10-year high
P/S against its own 10 years 56.85%
10-year low 10-year high
P/B against its own 10 years 96.00%
10-year low 10-year high
EV/Sales against its own 10 years 51.21%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1 4 4 9
Receivables 2 4 3 3
Inventory 8 7 9 9
Other — — — —
11 15 17 21
2023 2024 2025 Q'26
Payables 2 2 2 3
ST’ Debt 1 1 2 2
Other — — — —
4 4 4 4

Compound Annual Growth %

10y 5y 3y
Sales 10.45% 12.50% 14.19%
Cash Flow (1.57%) 13.48% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 9.81% (0.87%) (3.79%)

EPS $

Mar Jun Sep Dec Year
’26 0.21 0.20 — — —
’25 0.16 0.06 (0.02) (0.31) (0.12)
’24 (0.06) (0.20) (0.09) 0.06 (0.26)
’23 (0.30) (0.18) (0.12) (0.15) (0.75)
’22 0.07 (0.09) (0.08) (0.22) (0.32)
’21 (0.06) 0.02 0.02 0.01 (0.01)
’20 (0.02) (0.11) (0.04) 0.03 (0.14)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 10 7 — — —
’25 8 6 6 8 28
’24 7 5 6 8 26
’23 3 4 5 5 17
’22 6 4 5 4 19
’21 4 5 5 5 19
’20 5 3 4 4 15
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 4 3 — — —
’25 2 2 (1) 0 2
’24 0 1 (1) 0 0
’23 (3) (1) (1) (1) (5)
’22 1 0 (1) (1) (2)
’21 (1) 1 0 1 1
’20 1 1 (1) 0 1
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 3 2 — — —
’25 1 1 (2) 0 1
’24 0 0 (1) 0 0
’23 (3) (1) (1) (1) (7)
’22 0 (1) (2) (3) (6)
’21 (1) 0 0 0 (2)
’20 0 0 (2) 0 (3)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 10 10 11 14 15 19 19 17 26 28 31 +12.5% — — — —
Gross margin, % 56.80 50.06 47.28 49.11 44.73 44.98 41.19 22.15 29.97 41.40 40.32 (15.4) pt
EBT 1 0 (2) (1) (1) 0 (2) (6) (2) (1) 1 n/m
EBT margin, % 7.95 (4.20) (16.93) (9.24) (6.73) (0.36) (13.39) (33.02) (8.10) (3.72) 2.78 (11.7) pt
Net income 1 0 (2) (1) (1) 0 (2) (6) (2) (1) 1 n/m
Per share, $
Per share, $ Revenue 2.26 2.11 2.00 2.01 2.13 2.53 2.40 2.26 3.24 3.06 3.38 +3.4%
Earnings 0.12 (0.03) (0.42) (0.19) (0.14) (0.01) (0.32) (0.75) (0.26) (0.12) 0.08 n/m
Cash flow (0.05) 0.24 (0.07) 0.03 0.18 0.13 (0.20) (0.60) 0.04 0.27 0.65 n/m
Capex (0.84) (3.58) (0.32) (0.14) (0.56) (0.34) (0.51) (0.24) (0.06) (0.13) (0.18) (18.4%)
Free cash flow (0.89) (3.34) (0.39) (0.10) (0.38) (0.22) (0.71) (0.85) (0.01) 0.14 0.47 n/m
Book value 4.67 4.77 3.96 4.25 3.92 4.29 3.92 3.23 3.37 3.00 3.46 (4.8%)
Shares, m 4 5 5 7 7 8 8 8 8 9 9 +8.8%
Valuation, ×
Valuation, × P/E 43.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 117.02 4.3
P/S 2.63 3.92 3.52 2.56 2.80 3.16 2.70 2.22 1.59 2.01 2.93 2.7
P/B 1.28 1.73 1.78 1.21 1.52 1.86 1.65 1.55 1.53 2.05 2.86 1.6
EV/Sales 1.84 4.42 4.18 2.53 2.90 3.10 2.94 2.85 1.84 2.20 2.91 2.9
EV/FCF (4.64) (2.79) (21.33) (49.11) (16.40) (36.41) (9.92) (7.58) (472.81) 48.22 21.08 (57.3)
Cash, $m
Cash, $m Operating cash flow 0 1 0 0 1 1 (2) (5) 0 2 6 n/m
Capex (4) (18) (2) (1) (4) (3) (4) (2) 0 (1) (2) (11.3%)
Free cash flow (4) (17) (2) (1) (3) (2) (6) (7) 0 1 4 n/m
Balance, $m
Balance, $m Working capital 12 5 4 11 10 14 11 7 11 13 17 +0.6%
Net debt (8) 5 7 0 2 (1) 4 11 7 5 (1) n/m
Shareholders’ equity 20 24 22 29 28 33 30 25 28 27 31 +3.6%
Returns, %
Returns, % ROA 2.59 (0.57) (6.93) (3.63) (2.59) (0.18) (5.58) (13.03) (4.85) (2.37) 1.69 (5.0) pt
ROIC 4.59 (0.53) (3.12) (2.08) (2.89) 0.51 (4.13) (9.98) (2.99) 3.19 7.84 (1.4) pt
ROE 3.35 (0.78) (10.24) (5.11) (3.57) (0.26) (7.92) (20.86) (8.21) (3.81) 2.57 (7.2) pt
People
People Employees 45 47 51 54 61 67 74 79 75 73 — +5.5%
Revenue/emp, $m 0.21 0.22 0.22 0.25 0.25 0.29 0.25 0.22 0.35 0.38 — +6.7%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

ImmuCell Corporation vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
LENZ LENZ Therapeutics, Inc. $94.6M — (loss-making) — (loss-making) −72.93% (below 0%: shrinking) n/m −147.16% (below 0%: shrinking) 86.58% (972.75%) Compare
VANI Vivani Medical, Inc. $93.8M — (loss-making) — (loss-making) −71.87% (below 0%: shrinking) n/m +0.39% (above 0%: growing) 0.00% 0.00% Compare
VXRT VAXART, INC. $92.4M 2.8× — (loss-making) −85.33% (below 0%: shrinking) n/m −57.23% (below 0%: shrinking) 100.00% (162.74%) Compare
NMRA Neumora Therapeutics, Inc. $91.5M — (loss-making) — — n/m +24.45% (above 0%: growing) 0.00% 0.00% Compare
ICCC ImmuCell Corporation $90.4M 117× — (loss-making) +11.50% (above 0%: growing) +233.33% (above 0%: growing) +54.86% (above 0%: growing) 33.92% 26.93%
SEER Seer, Inc. $90.3M — (loss-making) — (loss-making) −23.43% (below 0%: shrinking) n/m +36.73% (above 0%: growing) 48.55% (542.91%) Compare
RTSN Retension Pharmaceuticals, Inc. $89.3M — — — — — — — Compare
CBUS Cibus, Inc. $87.1M — (loss-making) — (loss-making) +6.54% (above 0%: growing) n/m +31.62% (above 0%: growing) 100.00% (1,300.30%) Compare
PLYX Polaryx Therapeutics, Inc. $86.7M — (loss-making) — — n/m −93.09% (below 0%: shrinking) — 0.00% Compare
Median of peers $90.9M — — −71.87% — +0.39% 67.57% (162.74%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 24 April 2026

Ownership

Directors and executive officers, together 35.90%
Norman H., Sandra F., and Brian L. Pessin 13.10%
Ejnar A. Knudsen III 9.20%
Jonathan E. Rothschild 5.70%
SRK Capital, LLC 5.60%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

ImmuCell Corporation (ICCC) Latest News

12 Oct

Impact 4 · · GlobeNewswire

20 Aug

Impact 3 · · The Motley Fool transcript

14 Aug

Impact 4 · transcript
Impact 3 · · MarketBeat transcript
Impact 3 · · Moby transcript

13 Aug

Impact 3 ·

10 Jul

Impact 3 ·

9 Jul

Impact 3 ·

15 May

Impact 4 · · GuruFocus.com
Impact 3 · · MarketBeat
Impact 3 · · Moby transcript

14 May

Impact 3 · · GlobeNewswire

13 Apr

Impact 4 · · GlobeNewswire

8 Apr

Impact 4 · · GlobeNewswire

6 Mar

Impact 3 · · GuruFocus.com
Impact 3 · · Zacks

5 Mar

Impact 4 · · Moby
Impact 3 · · MarketBeat

4 Mar

Impact 4 · · GlobeNewswire

15 Jan

Impact 4 · · Zacks

12 Jan

Impact 3 · · Simply Wall St.

9 Jan

Impact 4 · · MarketBeat transcript

8 Jan

Impact 4 · · GlobeNewswire

7 Jan

Impact 4 · · GlobeNewswire

24 Dec

Impact 4 · · GlobeNewswireZacks

4 Dec

Impact 4 · · Zacks

24 Nov

Impact 4 · · GuruFocus.com transcript

13 Nov

Impact 3 · · GlobeNewswire

4 Nov

Impact 4 ·

1 Nov

Impact 3 · · Simply Wall St.
stockrow.com/ICCC · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com